Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0 First-in-human Clinical Trial of [203Pb]VMT-α-NET SPECT/CT for Somatostatin Receptor Imaging of Neuroendocrine Tumors

NCT05111509 is registered in ClinicalTrials.gov with Yusuf Menda as lead sponsor.

NCT NCT05111509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05111509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0 First-in-human Clinical Trial of [203Pb]VMT-α-NET SPECT/CT for Somatostatin Receptor Imaging of Neuroendocrine Tumors
Lead sponsor
Yusuf Menda
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 22, 2022
Completion date
June 30, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumor grade 1, neuroendocrine tumor grade 2